Nanogen Pharmaceutical Biotechnology Joint Stock Company is a leading company in the field of biotechnology in the Asia-Pacific region. We pioneer in the research and development of Active Pharmaceutical Ingredients (APIs) and specialized therapeutic products.
By applying advancements in recombinant DNA/protein technology, Nanogen has successfully provided a wide range of pharmaceuticals, from gene-based treatments to therapies for cancer, hepatitis B, hepatitis C, chronic kidney disease-related anemia, and many other conditions.
In addition to these achievements, Nanogen is also conducting research and clinical trials on monoclonal antibodies for cancer immunotherapy, as well as developing vaccines and treatments for the Covid-19.
Nanogen Pharmaceutical Biotechnology JSC. is committed to offering investors the opportunity to gain a deeper understanding of the company's operations through our company tour programs. This program is designed by Nanogen to provide investors with a comprehensive view of Nanogen's manufacturing, research, and development capabilities.
This program is available to all current and potential investors of Nanogen, including individual shareholders, investment organizations, and strategic partners.
Each company tour is designed for a maximum of 8 participants to ensure efficiency and safety. The program is divided into four parts as follows:
Investing in Nanogen is not only a financial decision but also an investment in the future of medicine. We are building a comprehensive biotechnology ecosystem, encompassing product research and development, international-standard manufacturing, and sustainable business practices. This ensures that Nanogen not only meets the current market demands but is also prepared to face future challenges.
As a shareholder of Nanogen, you empower us to fulfill our mission of innovating the healthcare industry, advancing scientific progress, and providing cutting-edge solutions to improve treatment outcomes for patients worldwide.
We are committed to sharing a long-term vision and sustainable growth with our valued shareholders. Our collaboration is aimed to build Nanogen into a symbol of innovation and leadership in the biotechnology sector, which will finally deliver lasting and sustainable value for all of us.
To facilitate the collaboration between Nanogen and future shareholders, our company is currently applying two forms of share offerings:
The offering price will be determined by Nanogen based on the market price at the time of the offering and may be adjusted to ensure competitiveness and attract investors. The offering price will be publicly announced and will remain unchanged throughout the offering period, except in cases of adjustments required by law or decisions made by the Board of Directors.
After investors complete the required procedures to become shareholders of Nanogen, the company will proceed with the transfer of shares according to regulations and update the new shareholders' information in the company's shareholder registry.
New shareholders will enjoy the same rights as existing shareholders, including voting rights, the right to receive dividends, and other benefits in accordance with the law and the company's charter.
Shareholders are responsible for complying with Nanogen's regulations and relevant laws concerning the ownership and transfer of shares.
Nanogen is committed to maintaining the confidentiality of personal and financial information for investors registering to purchase shares. This information will only be used for the purpose of executing the share purchase transactions and complying with legal regulations.
